Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HZ-A-018 in relapsed or refractory primary/secondary CNS lymphoma
ChiCTR2400091821Phase 2Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HZ-A-018 in central nervous system lymphoma and vitreoretinal lymphoma (PVRL), sponsored by Beijing Tiantan Hospital. Primary endpoints: Safety and tolerability, Maximum tolerated dose and recommended phase II dose and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
HZ-A-018
03
Conditions
central nervous system lymphomavitreoretinal lymphoma (PVRL)
Beyond the preview
Go deeper on ChiCTR2400091821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091821.